Analysis suggests tumor histology plays an important role in determining the best first-line approach for patients who have non–small cell lung cancer (NSCLC).
Although immunotherapy has become central to first-line treatment for non–small cell lung cancer (NSCLC), a recent study, highlighting squamous cell and non–squamous cell histology, suggests subtle differences in patient populations may be important in caring for patients in some NSCLC subgroups.
Study findings were published in Cancer Management and Research.
Since 2015, when the FDA approved nivolumab for treating metastatic NSCLC, immune checkpoint blockade has become a cornerstone of first-line treatment, particularly in the forms of programmed cell death-1 (PD-1), programmed cell death ligand-1 (PD-L1) and anti-cytotoxic T-lymphocyte–associated protein 4 (CTLA4), the authors wrote.
“Across all stages of NSCLC, immunotherapy has demonstrated its efficacy and become a major part of standard care,” the authors said.
In the present study, researchers sought to better understand cemiplimab-rwlc, a monoclonal antibody that works against programmed cell death. It was the third PD-1/PD-L1 inhibitor to be approved for first-line treatment in NSCLC, given as monotherapy or in combination with chemotherapy.
In conducting this review, they focused on subtle differences in patient populations for the cemiplimab studies, EMPOWER-Lung 1 and EMPOWER Lung-3, considering primary and subgroup results.
EMPOWER-Lung 1: Patients received cemiplimab monotherapy or chemotherapy. Based on study data, the FDA approved cemiplimab in February 2021 as first-line monotherapy for patients with advanced NSCLC with PD-L1 expression of at least 50% that was otherwise negative for EGFR, ALK, or ROS1 aberrations.
Three-year follow-up data were presented at the 2022 European Lung Cancer Congress (ELCC). Data included several subgroup analyses:
EMPOWER-Lung 3: Patients received cemiplimab plus chemotherapy or chemotherapy with placebo. Unlike most other chemotherapy and immunology trials, EMPOWER-Lung 3 enrolled patients irrespective of histology. Moreover, the trial included patients with stage IIIB/IIIC disease who were not candidates for definitive chemoradiation therapy. The cemiplimab-plus-chemotherapy group had a median OS of 21.9 months (95% CI, 15.5-NE) vs 13.0 months (95% CI, 11.9-16.1) in the chemotherapy-plus-placebo group (HR, 0.71; 95% CI, 0.53-0.93; P = .014).
Based on study data, in November 2022, the FDA approved cemiplimab in combination with platinum-based therapy for first-line treatment of adult patients with advanced NSCLC and no EGFR, ALK, or ROS1 aberrations, regardless of PD-L1 expression.
Two-year follow-up of the EMPOWER-Lung 3 study was presented at ELCC 2023. Overall, cemiplimab plus chemotherapy showed an improvement in survival, with a median OS of 21.1 months vs 12.9 months for chemotherapy with placebo (HR, 0.65; 95% CI, 0.51-0.82; P = .0003).
In a comparison by histology type, data showed the following:
Although the EMPOWER-Lung 3 subgroup analysis was not statistically powered, the cemiplimab-and-chemotherapy group demonstrated better results for PFS and OS in squamous histology compared with nonsquamous histology, the researchers said.
In addition, they compared NSCLC trials that used different immunotherapy agents (atezolizumab and pembrolizumab), looking at the squamous cell histology group. Although it is difficult to make a “head-to-head comparison between trials,” they noted, cemiplimab and chemotherapy appears to have better OS (22.3 vs 17.1 months) compared with the pembrolizumab-plus-chemotherapy group.
“Tumor histology appears to play an important role in determining efficacy of immunotherapy in combination with chemotherapy,” the authors concluded. “While it may not meet an ‘unmet need,’ the addition of another option for immunotherapy in NSCLC, as monotherapy or in combination with chemotherapy, may help us to better manage patients in a more personalized way.”
Reference
Ahn J, Nagasaka M. Spotlight on cemiplimab-rwlc in the treatment of non-small cell lung cancer (NSCLC): focus on patient selection and considerations. Cancer Manag Res. 2023;15:627-634. doi:10.2147/CMAR.S325856
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
Valoctocogene Roxaparvovec Dramatically Reduces Bleeding in Hemophilia A
May 15th 2024New study findings demonstrate that valoctocogene roxaparvovec, a gene therapy for severe hemophilia A, significantly reduces bleeding episodes and dependency on factor VIII infusions over a 3-year period, while maintaining a favorable safety profile.
Read More